Rice University Starts Up Biotech Venture Creation Enterprise for Medtech

Rice University has launched RBL LLC, a biotech venture creation studio aimed at enhancing patient care. The initiative is designed to swiftly develop companies that focus on lifesaving medical technologies originating from the Rice Biotech Launch Pad, the university’s accelerator for biotech innovation established last year.

The Rice Biotech Launch Pad will continue to provide RBL with fully developed and de-risked technologies from Rice’s life sciences portfolio, serving as a steady innovation pipeline for new ventures.

RBL will work to fast-track the journey “from bench to bedside” by leveraging a large portfolio of more than 100 patents from Rice faculty, bringing together scientists and engineers with experienced business executives to launch companies in a thriving biotech innovation environment.

Located in Houston’s Texas Medical Center Helix Park, RBL bridges the gap between academic biotech discoveries and the clinical care market. RBL’s location within the TMC provides greater opportunity to collaborate with premier clinical centers, corporate partners and global investors—all within the same complex—to rapidly bring therapies to patients by directly transforming Rice’s most promising life science technology into high impact ventures, company leaders said.

“Leveraging Rice University’s Biotech Launch Pad breakthroughs and pairing it with the translational infrastructure of TMC Helix Park well positions RBL to drive unprecedented advances in patient care,” TMC CEO William McKeon said. “This partnership between academia, industry and health care is exactly what’s needed to transform medical discoveries into real-world solutions that improve lives globally.”

RBL was co-founded by scientists, engineers, entrepreneurs, and investors including Paul Wotton, executive director of the Rice Biotech Launch Pad; Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

“This is a pivotal moment for Houston and beyond,” said Wotton, RBL’s managing partner. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems. Investors from across the nation are recognizing Houston’s potential, and with RBL, we’re building on that momentum. We’ll not only amplify the work of the Rice Biotech Launch Pad but expand our reach across Texas, creating opportunities for biotech ventures statewide and driving growth for the biotech industry as a whole.”

Rice President Reginald DesRoches said the company opens a “new chapter” in the way universities engage with the biotech industry.

“By forging a direct pipeline between our world-class research with clinical and commercial experts, we’re at the forefront of life sciences innovation,” DesRoches stated. “RBL will enable us to tackle some of the most pressing health care challenges globally by working with our partners in the Texas Medical Center to make therapeutics more accessible and affordable, while strengthening our leadership in Houston’s dynamic biotech innovation ecosystem.”

The creation of RBL from Rice was spearheaded by Paul Cherukuri, Rice’s chief innovation officer, and Veiseh, who recognized the need for launching a commercial entity to create multiple startup companies faster from newly developed biotechnology.

“RBL is a game-changer for Rice, Houston and the global biotech community,” Cherukuri declared. “This venture not only accelerates the commercialization of our innovations but also sets a blueprint for other universities looking to maximize the real-world impact of their discoveries. By combining scientific expertise with entrepreneurial support from Day Zero together with strategic clinical partnerships in the TMC, we’re creating a model for driving large-scale biotech innovation that universities everywhere should aspire to replicate.”

“RBL provides a powerful platform to translate high-impact scientific discoveries into therapies that will dramatically improve patient outcomes,” Veiseh added. “Our goal is to rapidly bring Rice’s research into the clinic, delivering lifesaving solutions to patients around the world.”

RBL’s formation was guided by Hogan Lovells US LLP with Houston partner Barry Burgdorf, representing Rice, playing a key role in its design and rollout, while Goodwin Procter LLP, representing RBL, ensured the transition from concept to execution.